Details for New Drug Application (NDA): 204114
✉ Email this page to a colleague
The generic ingredient in MEKINIST is trametinib dimethyl sulfoxide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the trametinib dimethyl sulfoxide profile page.
Summary for 204114
Tradename: | MEKINIST |
Applicant: | Novartis |
Ingredient: | trametinib dimethyl sulfoxide |
Patents: | 9 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 204114
Generic Entry Date for 204114*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 204114
Mechanism of Action | Protein Kinase Inhibitors |
Suppliers and Packaging for NDA: 204114
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
MEKINIST | trametinib dimethyl sulfoxide | TABLET;ORAL | 204114 | NDA | Novartis Pharmaceuticals Corporation | 0078-0668 | 0078-0668-15 | 30 TABLET, FILM COATED in 1 BOTTLE (0078-0668-15) |
MEKINIST | trametinib dimethyl sulfoxide | TABLET;ORAL | 204114 | NDA | Novartis Pharmaceuticals Corporation | 0078-1105 | 0078-1105-15 | 30 TABLET, FILM COATED in 1 BOTTLE (0078-1105-15) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 0.5MG | ||||
Approval Date: | May 29, 2013 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | Dec 22, 2024 | ||||||||
Regulatory Exclusivity Use: | PEDIATRIC EXCLUSIVITY | ||||||||
Regulatory Exclusivity Expiration: | Dec 22, 2025 | ||||||||
Regulatory Exclusivity Use: | PEDIATRIC EXCLUSIVITY | ||||||||
Regulatory Exclusivity Expiration: | Nov 4, 2025 | ||||||||
Regulatory Exclusivity Use: | PEDIATRIC EXCLUSIVITY |
Complete Access Available with Subscription